Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 5.

Noske, A; Loibl, S; Darb-Esfahani, S; Roller, M; Kronenwett, R; Müller, B M; Steffen, J; von Toerne, C; Wirtz, R; Baumann, I; Hoffmann, G; Heinrich, G; Grasshoff, S T; Ulmer, H U; Denkert, C; von Minckwitz, G (2011). Comparison of different approaches for assessment of HER2 expression on protein and mRNA level: prediction of chemotherapy response in the neoadjuvant GeparTrio trial (NCT00544765). Breast Cancer Research and Treatment, 126(1):109-117.

Loibl, S; Skacel, T; Nekljudova, V; Lück, H J; Schwenkglenks, M; Brodowicz, T; Zielinski, C; von Minckwitz, G (2011). Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer, 11:131.

Aapro, M; Schwenkglenks, M; Lyman, G H; Lopez Pousa, A; Lawrinson, S; Skacel, T; Bacon, P; von Minckwitz, G (2010). Pegfilgrastim primary prophylaxis vs. current practice neutropenia management in elderly breast cancer patients receiving chemotherapy. Critical Reviews in Oncology / Hematology, 74(3):203-210.

von Minckwitz, G; Schwenkglenks, M; Skacel, T; Lyman, G H; Lopez Pousa, A; Bacon, P; Easton, V; Aapro, M S (2009). Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis. European Journal of Cancer, 45(4):608-617.

von Minckwitz, G; Harder, S; Hövelmann, S; Jäger, E; Al-Batran, S E; Loibl, S G; Atmaca, A; Cimpoiasu, C; Neumann, A M; Abera, A; Knuth, A L; Kaufmann, M; Jäger, D; Maurer, A B; Wels, W S (2005). Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas. Breast Cancer Research, 7(5):R617.

This list was generated on Mon Sep 16 14:33:04 2019 CEST.